Fig. 7
From: The quest for nanoparticle-powered vaccines in cancer immunotherapy
CaP NPs loaded with disulfiram for improved cancer immunotherapy. A An illustration of the fabrication procedure for Cu-LCP/DSF NPs. The solution in tube A is cyclohexane/Igepal CO-520; the solution in tube B is cyclohexane/Triton-X 100/hexanol. B A schematic illustrating the combined Cu-LCP/DSF NPs and anti-PD-1 treatment schedule for the mouse model CT26. C Mice's weight after treatment. D CT26 tumor growth curves after different treatments in tumor-bearing mice. E Different treatments' tumor inhibitory rates based on tumor volume. F Images of different groups of mice with tumor slices stained with CRT and HMGB1. Adapted with permission from ref [274]. Copyright (2022) Biomaterials. DOPA, 1, 2-dioleoyl-sn-glycero-3-phosphate (sodium salt); DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine; DSPE-PEG5k, 1,2-distearoyl-snglycero-3-phosphoethanolamine-N- (methoxy (polyethylene glycol)-5000); LCP, lipid-coated calcium phosphate; DSF, Disulfiram; PD, programmed cell death; HMGB1, high mobility group box protein B1; CRT, calreticulin